MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock, net of...
$107,392,716
Proceeds from exercise of
stock warrants
$124,800
Proceeds from exercise of
stock options
$6,342
Net cash provided by
financing activities
$107,386,859
Effect of foreign
currency on cash
$3,842
Canceled cashflow
$136,999
Net change in cash
and cash...
$76,246,612
Canceled cashflow
$31,144,089
Payments of deferred
offering costs
$136,999
Stock-based compensation
$2,441,875
Tax receivable
-$2,059,507
Accounts payable and
accrued expenses
$1,027,161
Depreciation
$245,747
Amortization of right of use
asset
$118,754
Net cash used in
operating activities
-$23,930,304
Net cash used in
investing activities
-$7,213,785
Canceled cashflow
$5,893,044
Net loss
-$29,438,613
Purchase of short-term
investments
$6,480,860
Purchase of property and
equipment
$732,925
Prepaid expenses and
other current assets
$286,729
Operating lease liability
-$98,006
Back
Back
Cash Flow
source: myfinsight.com
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)